Destiny Pharma Share Discussion Threads

[gbjbaanb] 15/6/2021 12:00

He sold 0.6% so I don't exactly consider that anything other than getting himself a new TV and a few more toys. I think he still owns 10%

[malcolmmm] 15/6/2021 11:42

I did sell out but they look too low now ,looking to buy back in, most directors sell at some point as we all do

[garth] 10/6/2021 17:07

10 June 2021

Destiny Pharma plc

("Destiny Pharma" or the "Company")

Director Dealing

Destiny Pharma plc (AIM: DEST) a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, announces that it was notified on 10 June 2021 that on that same day, Dr William Love, Chief Scientific Officer of the Company, sold 350,000 ordinary shares of 1 pence in the Company ("Ordinary Shares") at a price of 120 pence.

Following the sale, Dr William Love's beneficial interest in the Company is 6,509,500 Ordinary Shares, representing 10.87 per cent. of the total issued share capital. Dr Love confirms that he does not intend to sell any further Ordinary Shares for the foreseeable future, that is until 2023 at the earliest.

[gbjbaanb] 10/6/2021 17:00

Someone obviously doesn't like the news!

[ttlance] 10/6/2021 07:53

Data to be presented from the successful Phase 2b clinical study of XF-73 nasal gel at the prestigious 2021 ECCMID congress



· XF-73 met its primary end point with >99% nasal S. aureus reduction within 24 hours

· Excellent clinical safety profile for XF-73 dosed in patients scheduled for cardiac surgery

· Infection prevention expert, Professor Julie Mangino MD to present XF-73 data abstract



Brighton, United Kingdom - 10th June 2021 - Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines to prevent life-threatening infections, today announces that an abstract providing analysis and discussion of the late-breaking data arising from the recently completed Phase 2b clinical study of XF-73 nasal gel has been accepted for presentation at Europe's premier antimicrobials congress, the 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), to be held 9 - 12 July, 2021.



Presentation Title: Repeated doses of exeporfinium chloride (XF-73) nasal gel over 24 hours significantly reduced the burden of Staphylococcus aureus nasal carriage in at-risk surgical patients: preliminary results from a Phase 2 study. The presentation will update the audience on the following highlights:



· Met primary endpoint: XF-73 reduced the mean nasal burden of S. aureus in patients undergoing open heart surgery by 2.5 log (CFU/ml) in the 24 hours immediately before surgery a highly statistically significant result, (p<0.0001). This equates to a 99.5% reduction in S. aureus bacterial nasal carriage, which is a very effective reduction by accepted clinical measures.

· XF-73 showed 2.1 log, (>99%), greater reduction than placebo in the same patient population and this difference in reduction of nasal burden of S. aureus was highly statistically significant (p<0.0001). The effect was maintained during surgery, considered the period when the risk for infections is the highest.

· These positive results were achieved with just three doses of 0.2% (w/w) XF-73 nasal gel in the 24 hours before incision and the start of surgery.

· There were no XF-73 nasal gel treatment related adverse events.

[sev22] 08/6/2021 19:23

Destiny Pharma (@DestinyPharma) Tweeted: Join Destiny Pharma at #BIODigital2021 on 10-11 June and 14-18 June seeking commercialisation partners for our two Phase 3-ready assets.

Listen to our presentation from June 10 at
#innovation #pharma #conference #biotech #infectionprevention

[edmonda] 07/6/2021 08:35

Momentum strong for Destiny's recently acquired asset M3, the AGM said timelines remain intact for both M3 and XF-73, and G7 highlights global threat of AMR.

Equity Development's fair value remains at 335p/ share in new research note here:

[sev22] 07/6/2021 08:03

Updated morning note from House broker:

G7 Health Ministers’ support for new antimicrobials.

The G7 Health Ministers issued a communique on 4 June 2021 highlighting the global threat of the “silent pandemic” of Antimicrobial Resistance (AMR) and the urgent need for the development of new treatments. They made clear that the G7 should support investment, regulatory and commercial incentives to companies such as Destiny Pharma, whose two Phase 3-ready assets (NTCD-M3 with FDA confirmation of Phase 3 design) speak to these very issues and fulfil in our opinion the criteria for government support and funding. We expect Destiny to pursue these avenues of funding for its two lead programmes (XF-73 and NTCD-M3), which are scheduled to start Phase 3 studies in 2022.

We reiterate our target valuation of 370p.

[sev22] 06/6/2021 20:33

Just to let all PIs know that a recording of the presentation: DESTINY PHARMA PLC - Annual General Meeting, along with responses to questions that were answered by the company are now available for review in the meeting archive at:



Just login for free to view the recording and Q&A. The presentation reinforces what a great investment case this company has.

The share price has drifted down since the excellent XF-73 results. However now there are two world class phase 3 trials in preparation for XF-73 and M3. Big pharma partner discussions are ongoing to get these trials funded and started.

I think DEST will have a lot of interest for both of these trials and likely be spoilt for choice with interested partners. They are in a great negotiating position and the market will eventually wake up to this as there are not many companies with such quality assets and on such a low valuation. The upside potential is massive.

[sev22] 02/6/2021 10:34

Dale Gerding provides an update on microbiome therapeutic NTCD-M3 for recurrent C. difficile infections.

[sev22] 02/6/2021 08:13

Updated note from House broker just released.

NTCD-M3 progress report – on track.

Destiny provided a positive progress report in respect of its lead clinical programme, NTCD-M3, following the asset’s acquisition in November 2020. The company remains on track to finalise the Phase 3 study design and for most of the manufacturing to be set up in 2021 so as to start the Phase 3 study in 2022. In addition, the company indicated that it has started discussions with potential licensing partners and collaborators with the aim of securing a partner to help fund the planned Phase 3 clinical study and participate in the future commercial launch of NTCD-M3. With timelines in line with forecasts and a cash runway that extends into Q4 2022, we reiterate our target valuation of 370p.

[t0pgrader] 02/6/2021 07:55

Confident-sounding RNS. Solid progress made in the last few weeks on all fronts preparing NTCDM3 for P3 next year.

[sicilian_kan] 01/6/2021 15:26

Agreed it is far, far too cheap for its lead asset and re the successful P2 results, with licensing deal expected to fund the P3 trial.

[supracat] 01/6/2021 09:28

Ty Sev. Been buying back I'm at these levels as way too cheap and do think some partnership updates and news is just around the corner. Possibly the AgM will give us more a sense of timing this week. Coukd easily see another 100p on the share price on the back of some partner agreement.

[sev22] 30/5/2021 16:42

Destiny Pharma PLC will use the Investor Meet Company platform to allow shareholders to follow proceedings of its annual general meeting on Thursday June 3rd, starting at 11.00 am and hear from the company via a live presentation and Q&A session immediately following the AGM.

The Company will also provide an online recording, available on the platform and the company's website after the meeting.

I expect the AGM and live presentation afterwards will provide more detail on what is going to happen in the rest of 2021 and into 2022 - exciting times!

Following outstanding Phase 2b data for XF-73 nasal, released in late March, and the acquisition last year of the global rights to NTCD-M3, the company has two Phase 3-ready assets.

Friday was a strong day. I think it is going to be a positive week.

[sev22] 21/5/2021 12:23

Potentially 250% upside from today's buy price of 1.335.

[sicilian_kan] 07/5/2021 08:39

"Partnering for XF-73 and NTCD-M3 Phase 3 targeted in 2021"